First Major Long COVID Cognitive Trial Finds No Single Effective Treatment
A landmark study published today reveals that three non-drug interventions showed similar, modest improvements in cognitive dysfunction associated with Long COVID, but none outperformed existing comparison groups, highlighting the ongoing challenge of treating this complex condition.
Meta Description: New research from the NIH RECOVER Initiative shows no single treatment significantly improves cognitive symptoms of Long COVID, but offers insights for future trials.
Long COVID, a chronic health condition affecting millions post-SARS-CoV-2 infection, continues to pose a significant medical challenge. Defined as symptoms lasting at least three months after initial infection, Long COVID can manifest in a wide range of debilitating ways. The National Institutes of Health (NIH) launched the Researching COVID to Enhance Recovery (RECOVER) Initiative to address this growing crisis, and the recently completed RECOVER-NEURO trial represents a crucial step forward in understanding and treating the neurological impacts of the disease.
The RECOVER-NEURO Trial: A Decentralized Approach
The RECOVER-NEURO Cognitive Dysfunction trial, coordinated by the Duke Clinical Research Institute, focused specifically on cognitive dysfunction – often described as “brain fog” – a common and distressing symptom of Long COVID. This dysfunction can include difficulties with memory, focus, and clear thinking. The study, conducted between August 2023 and December 2024, involved 328 adult patients across 22 sites in the United States and was published in JAMA Neurology.
A unique aspect of RECOVER-NEURO was its decentralized design, allowing participants to complete the majority of study activities from home over a 10-week period. This approach was intentionally implemented to reduce barriers to participation for individuals experiencing the profound fatigue and other debilitating symptoms often associated with Long COVID. “People living with Long COVID often experience profound fatigue and other disabling symptoms that can make attending in-person appointments challenging. To address this, we deliberately structured the trial to support remote participation whenever possible,” explained Jacqueline Becker, PhD, of Icahn School of Medicine at Mount Sinai and a multiple principal investigator of the study.
Treatment Approaches Examined
Participants were divided into five groups: three receiving active treatments and two serving as comparison groups. The active treatment groups explored the following interventions:
- BrainHQ: An interactive online brain training program developed by Posit Science, Inc., designed to improve memory, attention, and processing speed.
- BrainHQ + PASC-Cognitive Recovery (PASC-CoRE): A combination of the BrainHQ program with a virtually delivered, small group cognitive rehabilitation program focused on strategies for managing distractions and mental fatigue. This component was administered by Mount Sinai and Emory University.
- BrainHQ + Transcranial Direct Current Stimulation (tDCS): A combination of BrainHQ with a non-invasive brain stimulation technique using a specialized cap delivering a mild electrical current. New York University coordinated this portion of the trial.
The comparison groups received either a computer puzzle and game program visually similar to BrainHQ, but lacking its interactive features, or BrainHQ combined with a non-functional tDCS device.
Modest Improvements, No Clear Winner
Despite the diverse approaches, the study found that none of the rehabilitation strategies proved definitively effective. “None of our rehabilitation approaches to treatment for cognitive Long COVID proved to be effective. Detecting a benefit for one of the interventions was made more difficult because participants in all 5 treatment arms showed modest improvements,” stated David Knopman, MD, of the Mayo Clinic and lead author of the study.
The researchers emphasized that the modest improvements observed across all groups suggest a potential benefit from engagement in cognitive activities, regardless of the specific intervention. However, the lack of a clear standout treatment underscores the complexity of Long COVID and the need for further research.
Implications for Future Research
RECOVER-NEURO represents a critical early step in the investigation of Long COVID treatments. According to the study authors, the findings will inform the design of future clinical trials. The RECOVER Initiative is currently conducting seven additional studies exploring various treatments for the diverse symptoms experienced by Long COVID patients.
The full list of trial sites is available on ClinicalTrials.gov, and more details on all RECOVER trials can be found at trials.recoverCOVID.org. This research highlights the urgent need for continued investigation into effective therapies for this debilitating condition.
- WWE SmackDown Results – August 7, 2026 (archyde.com)
